REG - Kromek Group PLC - Kromek and Analogic Collaboration Agreement

KromekAnnouncement

19/04/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230419:nRSS6653Wa&default-theme=true

RNS Number : 6653W  Kromek Group PLC  19 April 2023

19 April 2023

Kromek Group plc

("Kromek" or the "Group")

 

Kromek and Analogic Announce Collaboration Agreement to Develop Next
Generation

Computed Tomography (CT) Detector Technology

CZT-based Photon Counting CT technology is poised to enable imaging and
detection breakthroughs

not achievable with conventional technology

 

Kromek Group plc (AIM: KMK) and Analogic Corporation today announced they have
entered into an agreement to collaborate on the development of next-generation
Cadmium Zinc Telluride (CZT) based detector solutions for Photon Counting
Computed Tomography (PCCT) applications in the medical imaging and security
sectors.

 

CZT-based PCCT detectors overcome limitations inherent in conventional CT
detectors to deliver improvements in spatial resolution, radiation dose
reduction and energy resolution. This innovative technology can result in
improved image quality whilst also providing a gateway to material
characterization and quantitative results allowing early detection of
life-threatening illness such as breast cancer or heart disease when used in
medical imaging.  In security screening, the improved image quality and 3D
images of passenger bags and parcels will allow passengers to keep luggage in
their bag whilst accurately identifying prohibited and dangerous items in real
time.

 

As part of the collaboration, Kromek will integrate CZT sensors with
Analogic's detector designs to ensure optimal detection system performance.
As the project progresses toward commercialisation, the Group will ensure
production capability is available to support Analogic's PCCT demand.

 

As global leaders in CT detector technology for over 50 years, Analogic
continues to advance its product offering of systems and subsystems in both
security and medical imaging applications. Its PCCT technology is designed to
enable new system solutions as well as upgraded options for installed systems.

 

Arnab Basu, CEO of Kromek, said: "At Kromek we are constantly looking to team
up with leading global organisations who match our vision and desire to
improve patient outcomes as well as combine our technologies to enhance the
safety of our citizens. Analogic has a long track record in doing just this
and we are looking forward to our collaboration to enable Analogic to bring
the next generation of CT scanners to the market."

 

Tom Ripp, Analogic CEO, said: "As pioneers in CT imaging and detection
technology, we are excited about this collaboration with Kromek to bring the
next generation of PCCT detection solutions to market." Mr. Ripp continued:
"This project underscores Analogic's desire to make the world a healthier and
safer place for patients and passengers globally."

 

 

For further information, please contact:

 

 Kromek Group plc
 Arnab Basu, CEO                                                               +44 (0)1740 626 060

 Paul Farquhar, CFO

 finnCap Ltd (Nominated Adviser and Broker)                                     
 Geoff Nash/Emily Watts/Seamus Fricker/George Dollemore  Corporate Finance     +44 (0)20 7220 0500

 Tim Redfern/Charlotte Sutcliffe - ECM

 Gracechurch Group (Financial PR)
 Harry Chathli/Claire Norbury                                                  +44 (0)20 4582 3500

Kromek Group plc

 

Kromek Group plc is a leading developer of radiation detection and
bio-detection technology solutions for the advanced imaging and CBRN detection
segments. Headquartered in County Durham, UK, Kromek has manufacturing
operations in the UK and US, delivering on the vision of enhancing the quality
of life through innovative detection technology solutions.

 

The advanced imaging segment comprises the medical (including CT and SPECT),
security and industrial markets. Kromek provides its OEM customers with
detector components, based on its core cadmium zinc telluride (CZT) platform,
to enable better detection of diseases such as cancer and Alzheimer's,
contamination in industrial manufacture and explosives in aviation
settings.

 

In CBRN detection, the Group provides nuclear radiation detection solutions to
the global homeland defence and security market. Kromek's compact, handheld,
high-performance radiation detectors, based on advanced scintillation
technology, are primarily used to protect critical infrastructure and urban
environments from the threat of 'dirty bombs'.

 

The Group is also developing bio-security solutions in the CBRN detection
segment. These consist of fully automated and autonomous systems to detect a
wide range of airborne pathogens.

 

Kromek is listed on AIM, a market of the London Stock Exchange, under the
trading symbol 'KMK'.

Further information is available at www.kromek.com (http://www.kromek.com/)
.

 

Analogic Corporation

 

Analogic Corporation, headquartered in Peabody, MA, USA, is a global leader in
design, development manufacturing and support of technically advanced and
cost-effective imaging & detection and power & automation solutions
for security, healthcare, and other high-end industrial markets.  Analogic
has been a leader in the field of Computed Tomography for over 40 years, with
technology installed in over 60,000 CT systems deployed worldwide.  For more
information, please visit www.analogic.com (http://www.analogic.com) .

 

Contact:

 

Jason Plante
 
+1 (216) 645-6113

VP, Medical Imaging

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEANLPFLDDEFA